Literature DB >> 20959363

MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries.

Radhika R Tunstall1, Praveen Shukla, Anna Grazul-Bilska, Chengwen Sun, Stephen T O'Rourke.   

Abstract

Previous studies from our laboratory demonstrated that melatonin inhibits nitric oxide (NO)-induced relaxation in porcine coronary arteries. The present study was designed to further characterize the mechanisms underlying this inhibitory effect of melatonin. Western immunoblot studies identified the presence of melatonin type 2 (MT(2)) receptors, but not MT(1) or MT(3) receptors, in porcine coronary arteries. Immunohistochemical analysis revealed that MT(2) receptors colocalized with α-actin in the smooth muscle cell layer. In coronary arterial rings suspended in organ chambers for isometric tension recording, melatonin (10(-7) M) inhibited relaxations induced by the exogenous NO donor sodium nitroprusside (SNP; 10(-9) to 10(-5) M) and by the α(2)-adrenoceptor agonist 5-bromo-6-[2-imidazolin-2-yl-amino]-quinoxaline (UK14,304; 10(-9) to 10(-5) M), an endothelium-dependent vasodilator. The inhibitory effect of melatonin on SNP- and UK14,304-induced relaxations was abolished in the presence of the selective MT(2) receptor antagonists 4-phenyl-2-propionamidotetralin (4P-PDOT; 10(-7) M) and luzindole (10(-7) M). In contrast to melatonin, the selective MT(3) receptor agonist 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT; 10(-7) M) had no effect on the concentration-response curves to either SNP or UK14,304. Melatonin (10(-7) M) had no effect on coronary artery relaxation induced by 8-bromoguanosine 3',5'-cyclic monophosphate, but it significantly attenuated the increase in intracellular cyclic GMP levels in response to SNP (10(-5) M). This effect of melatonin was abolished in the presence of 4P-PDOT (10(-7) M). Taken together, these data support the view that melatonin acts on MT(2) receptors in coronary vascular smooth muscle cells to inhibit NO-induced increases in cyclic GMP and coronary arterial relaxation, thus demonstrating a novel function for MT(2) receptors in the vasculature.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959363      PMCID: PMC3014306          DOI: 10.1124/jpet.110.174482

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  43 in total

Review 1.  Extrapineal melatonin: location and role within diffuse neuroendocrine system.

Authors:  I M Kvetnoy
Journal:  Histochem J       Date:  1999-01

2.  Melatonin receptors mediate contraction of a rat cerebral artery.

Authors:  M Viswanathan; E Scalbert; P Delagrange; B Guardiola-Lemaître; J M Saavedra
Journal:  Neuroreport       Date:  1997-12-22       Impact factor: 1.837

3.  Melatonin mediates two distinct responses in vascular smooth muscle.

Authors:  S Doolen; D N Krause; M L Dubocovich; S P Duckles
Journal:  Eur J Pharmacol       Date:  1998-03-12       Impact factor: 4.432

4.  Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.

Authors:  L J Ignarro; H Lippton; J C Edwards; W H Baricos; A L Hyman; P J Kadowitz; C A Gruetter
Journal:  J Pharmacol Exp Ther       Date:  1981-09       Impact factor: 4.030

Review 5.  Cyclic guanosine monophosphate as a mediator of vasodilation.

Authors:  F Murad
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

6.  Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells.

Authors:  Ina Stumpf; Eckhard Mühlbauer; Elmar Peschke
Journal:  J Pineal Res       Date:  2008-03-25       Impact factor: 13.007

7.  Decreased MT1 and MT2 melatonin receptor expression in extrapineal tissues of the rat during physiological aging.

Authors:  Marina Sánchez-Hidalgo; Juan Miguel Guerrero Montávez; María Del Pilar Carrascosa-Salmoral; María Del Carmen Naranjo Gutierrez; Patricia Judith Lardone; Catalina Alarcón de la Lastra Romero
Journal:  J Pineal Res       Date:  2008-05-28       Impact factor: 13.007

8.  Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure.

Authors:  Luis Girotti; Manuel Lago; Oscar Ianovsky; Marcelo V Elizari; Andrés Dini; Santiago Pérez Lloret; Liliana E Albornoz; Daniel P Cardinali
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

9.  The melatonin receptor subtype MT2 is present in the human cardiovascular system.

Authors:  Cem Ekmekcioglu; Theresia Thalhammer; Susanne Humpeler; Mohammad R Mehrabi; Helmut D Glogar; Thomas Hölzenbein; Ognjen Markovic; Valentin J Leibetseder; Gerhard Strauss-Blasche; Wolfgang Marktl
Journal:  J Pineal Res       Date:  2003-08       Impact factor: 13.007

Review 10.  Molecular pharmacology, regulation and function of mammalian melatonin receptors.

Authors:  Margarita L Dubocovich; Moises A Rivera-Bermudez; Matthew J Gerdin; Monica I Masana
Journal:  Front Biosci       Date:  2003-09-01
View more
  16 in total

1.  Modulation of mesenteric collecting lymphatic contractions by σ1-receptor activation and nitric oxide production.

Authors:  Andrea N Trujillo; Christopher Katnik; Javier Cuevas; Byeong Jake Cha; Thomas E Taylor-Clark; Jerome W Breslin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-08-04       Impact factor: 4.733

2.  Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats.

Authors:  Ajaykumar N Sharma; Ashish Pise; Jay N Sharma; Praveen Shukla
Journal:  Metab Brain Dis       Date:  2014-11-08       Impact factor: 3.584

3.  Melatonin MT2 receptor is expressed and potentiates contraction in human airway smooth muscle.

Authors:  Haruka Sasaki; Yi Zhang; Charles W Emala; Kentaro Mizuta
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-06       Impact factor: 5.464

4.  Maternal nutrient restriction during pregnancy impairs an endothelium-derived hyperpolarizing factor-like pathway in sheep fetal coronary arteries.

Authors:  Praveen Shukla; Srinivas Ghatta; Nidhi Dubey; Caleb O Lemley; Mary Lynn Johnson; Amit Modgil; Kimberly Vonnahme; Joel S Caton; Lawrence P Reynolds; Chengwen Sun; Stephen T O'Rourke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-09       Impact factor: 4.733

5.  Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells.

Authors:  Juanita Dortch-Carnes; Gianluca Tosini
Journal:  Exp Eye Res       Date:  2012-11-29       Impact factor: 3.467

6.  Activation of Large Conductance, Calcium-Activated Potassium Channels by Nitric Oxide Mediates Apelin-Induced Relaxation of Isolated Rat Coronary Arteries.

Authors:  Amreen Mughal; Chengwen Sun; Stephen T O'Rourke
Journal:  J Pharmacol Exp Ther       Date:  2018-05-17       Impact factor: 4.030

7.  Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries.

Authors:  Praveen Shukla; Chengwen Sun; Stephen T O'Rourke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-19       Impact factor: 4.733

Review 8.  Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension.

Authors:  Natalia Jorgelina Prado; León Ferder; Walter Manucha; Emiliano Raúl Diez
Journal:  Curr Hypertens Rep       Date:  2018-05-09       Impact factor: 5.369

9.  Apelin Does Not Impair Coronary Artery Relaxation Mediated by Nitric Oxide-Induced Activation of BKCa Channels.

Authors:  Amreen Mughal; Chengwen Sun; Stephen T O'Rourke
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

Review 10.  Melatonin for the Management of Preeclampsia: A Review.

Authors:  Annie Langston-Cox; Sarah A Marshall; Daisy Lu; Kirsten R Palmer; Euan M Wallace
Journal:  Antioxidants (Basel)       Date:  2021-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.